维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

5篇 您的检索式：作者名="S.Hsu"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Isolation and characterization of lactic acid bacteria from dochi (fermented black beans), a traditional fermented food in Taiwan显示文摘	Y.‐S.Chen F.Yanagida J.‐S.Hsu	2006	Letters in Applied Microbiology2006，，2：	1
	2	Impact of hepatitis B virus infection on metabolic profiles and modifying factors显示文摘	C.‐S.Hsu C.‐H.Liu C.‐C.Wang T.‐C.Tseng C.‐J.Liu C.‐L.Chen P.‐J.Chen D.‐S.Chen J.‐H.Kao	2012	Journal of Viral Hepatitis2012，，2：	1
	3	Viscoelastic Changes of Rice Starch Suspensions During Gelatinization显示文摘	S.Hsu S.Lu C.Huang	2008	Journal of Food Science2008，，2：	1
	4	Predictive and prognostic biomarkers in colorectal cancer显示文摘Colorectal cancer is the third most common cancer and the second leading cause of cancer-related death in the United States.Three quarters of patients diagnosed with colorectal cancer will have early stage disease and despite surgical resection for curative intent,approximately 20%-25%of patients will recur with their disease within five years.The other 25%will present with advanced or metastatic disease and clinicians are faced with the challenge of choosing the most appropriate therapy for individual patients.Despite multiple treatment options which are now available and concomitant improvements in survival,advanced colorectal cancer remains universally fatal.The challenge for clinicians is to identify prognostic and predictive biomarkers that can assist in tailoring available treatments for an individual patient to improve clinical outcomes.This review will summarize current and future biomarkers in colorectal cancer and discuss their utility in managing patient care.	Jeffrey Van DEUSEN David S.HSU	2011	Frontiers in Biology2011，6，6：	0
	5	Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance显示文摘Colorectal cancer is a leading cause of cancer deaths.Most colorectal cancer patients eventually develop chemoresistance to the current standard-of-care therapies.Here,we used patient-derived colorectal cancer organoids to demonstrate that resistant tumor cells undergo significant chromatin changes in response to oxaliplatin treatment.Integrated transcriptomic and chromatin accessibility analyses using ATAC-Seq and RNA-Seq identified a group of genes associated with significantly increased chromatin accessibility and upregulated gene expression.CRISPR/Cas9 silencing of fibroblast growth factor receptor 1(FGFR1)and oxytocin receptor(OXTR)helped overcome oxaliplatin resistance.Similarly,treatment with oxaliplatin in combination with an FGFR1 inhibitor(PD166866)or an antagonist of OXTR(L-368,899)suppressed chemoresistant organoids.However,oxaliplatin treatment did not activate either FGFR1 or OXTR expression in another resistant organoid,suggesting that chromatin accessibility changes are patient-specific.The use of patient-derived cancer organoids in combination with transcriptomic and chromatin profiling may lead to precision treatments to overcome chemoresistance in colorectal cancer.	Kuei-Ling Tung Kai-Yuan Chen Marcos Negrete Tianyi Chen Alexias Safi Abed Alhalim Aljamal Lingyun Song Gregory E.Crawford Shengli Ding David S.Hsu Xiling Shen	2021	Genes & Diseases2021，8，2：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费